COMMUNIQUÉS West-GlobeNewswire

MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
07/03/2024
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024 Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADC Preclinical [...]
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
07/03/2024
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc [...]
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
07/03/2024
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met All [...]
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
07/03/2024
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in non-invasive [...]
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
07/03/2024
Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF. Screening of patients is resuming in [...]
Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH
07/03/2024
Inventiva a levé la pause volontaire du screening et de la randomisation pour l’étude clinique NATiV3 à la suite de l’approbations par l’ IRB central américain du protocole et de l’ ICF amendés. Le screening des [...]
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
07/03/2024
NRTX-1001 is being evaluated in an ongoing Phase I/II clinical trial in adults with drug-resistant focal epilepsy SAN FRANCISCO, March 07, 2024 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
07/03/2024
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – March 07, 2024 – 07:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, [...]
MAPS Announces Celestial Plans for Its 38th Anniversary
07/03/2024
MAPS, which celebrates its 38th anniversary on April 8, 2024, will celebrate with a total solar eclipse at the Texas Eclipse 2024 festival outside of Austin, Texas. Festival highlights include over 300 musical artists, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 29, 2024
07/03/2024
Disclosure of Share Capital and Voting Rights Outstanding as of February 29, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 29 février 2024
07/03/2024
Nombre total de droits de vote et d’actions composant le capital social au 29 février 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
07/03/2024
BOSTON and ROLLE, Switzerland, March 07, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced Chief Financial Officer and Chief [...]
EssilorLuxottica and Dolce&Gabbana announce 16-year licensing renewal
07/03/2024
EssilorLuxottica and Dolce&Gabbana announce 16-year licensing renewal Charenton-le-Pont, France and Milan, Italy (March 7, 2024) - EssilorLuxottica and Dolce&Gabbana, today, announce the early renewal of their [...]
EssilorLuxottica et Dolce&Gabbana annoncent le renouvellement de leur accord de licence pour 16 ans
07/03/2024
EssilorLuxottica et Dolce&Gabbana annoncent le renouvellement de leur accord de licence pour 16 ans Charenton -le-Pont, France et Milan, Italie (7 mars 2024) - EssilorLuxottica et Dolce&Gabbana annoncent aujourd [...]
DLH to Provide Information Technology Services to the National Cancer Institute
07/03/2024
ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading Health IT provider of digital transformation and cybersecurity, science research and development, and [...]
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
07/03/2024
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation [...]
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/03/2024
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerce et à l’article 223-16 du Règlement Général de l’ [...]
Healthcare Financial Management Association calls Patient Rights Advocate’s latest price transparency compliance report ‘irresponsible’
07/03/2024
CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) -- Long an advocate for consumerism and price transparency in healthcare, the Healthcare Financial Management Association (HFMA) today called the latest report from Patient [...]
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
07/03/2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients LISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX ), a U.S [...]

Pages